Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01272635 · ClinicalTrials.gov registry record · Phase 3

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

A Phase 3 study, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
Phase 3
Development phase
607
Enrollment target

NCT01272635: Completed Phase 3 study, sponsored by Milton S. Hershey Medical Center.

NCT01272635 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 607 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01272635, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
607 participants
Enrollment target

Study Summary

This protocol is comprised of two separate, but linked, clinical trials for treating preschool-aged children with recurrent severe episodes of wheezing. The first study (APRIL) will try to prevent wheezing illness from developing using azithromycin. If a wheezing illness does occur, the second trial (OCELOT) will try to decrease the severity of symptoms using oral corticosteroids.

Primary Outcome

Progression to clinically significant lower respiratory tract symptoms defined by: (1) having symptoms that were more than mild after 3 albuterol administrations over 1 hour, or (2) requiring albuterol administrations more often than once every 4 hours, or (3) requiring more than 6 albuterol treatments over a 24-hour period, or (4) having moderate to severe cough or wheeze for 5 or more days since study medication was initiated.

Interventions

  • DRUG Azithromycin
  • DRUG Prednisolone
  • OTHER Placebo Azithromycin
  • DRUG Placebo Prednisolone

Trial Details

FieldValue
Enrollment Target 607 participants
Start Date 2011-03
Est. Completion 2015-01
Phase Phase 3
Milton S. Hershey Medical Center

396 total trials

What the finished NCT01272635 record still lists

NCT01272635 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).

The record links to 0 conditions, and to 4 interventions - of which Azithromycin is the first listed.

NCT01272635 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01272635 about?

NCT01272635 is a clinical study titled "Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.". This protocol is comprised of two separate, but linked, clinical trials for treating preschool-aged children with recurrent severe episodes of wheezing. The first study (APRIL) will try to prevent wheezing illness from developing using azithromycin. If a wheezing illness does occur, the second trial...

What is the current status of trial NCT01272635?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2011-03. Estimated completion is 2015-01.

What interventions are being tested in trial NCT01272635?

The interventions under investigation include: Azithromycin (DRUG), Prednisolone (DRUG), Placebo Azithromycin (OTHER), Placebo Prednisolone (DRUG).

Who is sponsoring clinical trial NCT01272635?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01272635's enrollment target sits among peer trials

607 605th of 2000 higher than 1,395 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02064673 · 608 participants · Phase 3

    Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

  • NCT06091202 · 608 participants · Phase 3

    Tele-Collaborative Outreach to Rural Patients With Chronic Pain

  • NCT06098144 · 608 participants · Phase 4

    Smoking Cessation Program in the Construction Sector

  • NCT02342444 · 606 participants · Phase 4

    Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01272635, the US trial registry maintained by the National Library of Medicine. NCT01272635 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.